FREE Daily Stock Alerts From Stock-PR.com
Proper Power & Energy, Inc. (OTC Bulletin Board:PPWE.ob) commented just recently on a Wall Street Journal Article titled “Oil’s Rise Is a Sticky Situation for Recovery”. (Dated January 12, 2011 Section C). The article discussed the current environment of rising oil prices and its effect on consumers and the impending economic recovery. With oil prices at nearly $90 per barrel, consumers fear oil prices will return to their 2008 levels, when oil peaked over $145 per barrel. “A 2008 – style shock isn’t a certainty, but an upward trend is clear. Goldman Sachs expects oil prices to average $100 a barrel this year….,” the article is quoted as saying.
Proper Power has begun production on its Kentucky oil asset, in addition to the 11,000 acres leased for its exploratory prospect in Utah. The Utah prospect has the potential for over 75 wells. The Company believes the Utah property holds very substantial recoverable reserves, indicated through seismic and radiometric analysis.
“The Company will benefit from these rising prices as it produces its Kentucky oil asset while creating the strategy for our exploration prospect in Utah,” stated President of American Resources, Andrew J. Kacic. American Resources is a wholly owned subsidiary of Proper Power.
“Having met with Mr. Dunbar, and through verifying the Company’s data with industry relationships, I believe Utah is a viable exploratory prospect,” stated Douglas Kiggins, Proper Power Advisor. “In further due diligence, the Anshultz Ranch field, located southwest from the Proper Power prospect, has produced One Billion B.O.E. (Barrels of Equivalent) to date, on the same geological structure as Proper Power’s.”
About Proper Power & Energy:
Proper Power & Energy was formed in 2006 as an exploration and production company for oil and gas. The organization is committed to utilizing a very dynamic system of research and testing, and as a result of this extensive research and testing, have selected several sites with very good to excellent potential for productivity.
Power3 Medical Products, Inc. (OTC:PWRM)
Power3 Medical Products, Inc. (OTC.BB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, recently announced that company management believes it is making great progress in its focus on the development, sales, and marketing of its proprietary innovate diagnostic tests for breast cancer, pancreatic cancer, ovarian cancer, colon cancer, and certain neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, to name a few.
In addition, Power3 is a party to several litigation matters, most of which relate to various toxic debt instruments that were entered into by Power3 several years ago when it operated under the tenure of Chairman and CEO, Steven B. Rash. Because current management believes these toxic debt instruments are responsible for Power3’s depressed stock price and have distracted the company from its mission, Power3 plans to settle as many of these nagging lawsuits as possible prior to the completion of its merger with Rozetta-Cell Life Sciences, Inc. As for those lawsuits that cannot be speedily resolved, Power3 will continue to rigorously defend its position. For example, one such lawsuit involves Neogenomics, Inc., which was recently granted a motion for summary judgment with respect to an amount due under a convertible debenture. Power3 intends to appeal this decision.
“We are very excited to be finally ridding ourselves of litigation that has plagued us for several years now,” stated Ira L. Goldknopf, President and Chief Scientific Officer of Power3 Medical Products, Inc. “We have big plans for the future beginning with our upcoming acquisition of Rozetta-Cell and are about to enter a long and substantial growth phase marked by advances in our science and intellectual property. Given the imminent nature of many of these transactions and breakthroughs, we have decided, in consultation with the financiers of Rozetta-Cell, that the best course of action for Power3 is to settle many of these lawsuits so that we can focus our attention exclusively on the acquisition of Rozetta-Cell and the development of our combined businesses after the merger.”
Rozetta-Cell Life Sciences, Inc. is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. Power3 plans to effect the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company. The acquisition of Rozetta-Cell is expected to be completed in February 2011.
Alzheimer’s disease is among the most well known form of dementia, a broad term when it comes to forgetfulness and other intellectual abilities critical enough to obstruct everyday life. Alzheimer’s diseases is the reason for 50 to seventy per cent of dementia cases.
Breast cancer (malignant breast neoplasm) is cancer originating from breast tissue, most frequently belonging to the inner lining of milk ducts as well as lobules that offer the ducts with milk. Cancers originating from ducts are known as ductal carcinomas; those originating from lobules are classified as lobular carcinomas.
As symptoms get worse, individuals with Parkinson’s disease may have trouble walking, talking or doing simple tasks. They may also have problems such as depression, sleep problems or trouble chewing, swallowing or speaking.
Arrow Electronics, Inc. (NYSE:ARW) announced that it has signed a distribution agreement with Janus Remote Communications, a leader in Machine-to-Machine (M2M) communications. Janus provides cellular-enabled devices for data acquisition and telemetry, asset tracking, facility and equipment monitoring, smart utilities and security applications. Under the new agreement, Arrow will distribute Janus Terminus platform devices in the Americas regions. The Terminus platform encompasses cellular communication terminals from simple telemetry devices through intelligent control terminals, in a wide array of package options.
Arrow Electronics, Inc. distributes a range of electronic components and enterprise computing products, services, and solutions to industrial and commercial users worldwide. The company operates in two segments, Global Components and Global Enterprise Computing Solutions.
Esterline Technologies Corp. (NYSE:ESL) a leading specialty manufacturer serving aerospace and defense markets, announced that Dr. Delores M. Etter has been appointed to the company's Board of Directors. Brad Lawrence, Esterline CEO, said, "We were delighted to have such an accomplished executive as Dr. Etter joining our Board. Her extensive scientific and engineering background, industry knowledge and Department of Defense experience were very well suited to Esterline, especially as those talents relate to several key areas where we have growth plans."
Esterline Technologies Corporation designs, manufactures, and markets engineered products and systems for the aerospace and defense, industrial/commercial, and medical markets primarily in the United States and Europe.
Allegheny Technologies Inc. (NYSE:ATI) will provide live Internet listening access to its conference call with investors and analysts scheduled for January 26, 2011, at 1:00 p.m. ET. The conference call will be conducted after the Company’s planned release of fourth quarter and full year 2010 results. The conference call will be broadcast at www.ATImetals.com. To access the broadcast, go to the home page and select “Conference Call”. Replay of the conference call will be available on the ATI website.
Allegheny Technologies Incorporated produces and sells specialty metals worldwide. The company’s High Performance Metals segment offers a range of high performance alloys, including nickel-and cobalt-based alloys and superalloys; titanium and titanium-based alloys; exotic metals.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) anticipates receiving 1,000,000 shares of free trading shares from a third party (Mohamad Nehmeh) for two (2) weeks of advertisment services for Proper Power & Energy, Inc. (OTC:PPWE). Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).
Sign Up For Free Stock Alerts At http://stock-pr.com/signup
________________________________________Be Sure To Visit stock-pr.ning.com
The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.